Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction

Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism

“…Clinical investigations have reported that eosinophils are increased in the sputum and bronchial biopsies of patients with AECOPD (31,32). Increased levels of ECP in serum (24,33), bronchoalveolar lavage fluid (34) and induced sputum (35) have been observed in patients with AECOPD. Hospers et al (20) proposed that peripheral blood eosinophilia may also lead to a higher mortality rate for patients with AECOPD.…”

“…Although the plasma levels of ECP, EDN, EPX and MBP were upregulated in the AECOPD and AECOPD/PE groups in the present study, ECP and EDN were the most potent biomarkers for predicting AECOPD and AECOPD/PE. Fiorini et al (24) reported that ECP measured by radioimmunoassay did not increase significantly in patients with stable COPD (24). This suggests that eosinophil activation is not involved in the stable stage of COPD; however, in the acute stage of severe COPD, eosinophil activation appears to be crucial and thus eosinophil secretory proteins, particularly ECP and EDN, are likely to be key clinical indicators for AECOPD.…”

“…ECP also induces airway mucus secretion and interacts with the coagulation and complement systems (22,23). Fiorini et al (24) concluded that serum ECP levels increased during AECOPD. Shahana et al (25) reported that MBP secreted by eosinophils induced the apoptosis of bronchial airway epithelial cells, leading to airway epithelial shedding and blister formation.…”

“…The role of eosinophil activation in the development of AECOPD with or without PE is unclear. Although ECP is increased in people with AECOPD (24), measuring this protein alone is insufficient to establish a correlation between eosinophil activation and AECOPD with or without PE. In the present study, the plasma levels of ECP, MBP, EPX and EDN were measured to assess and clarify the association between eosinophil activation and the development of AECOPD with or without PE.…”

Vasoactive intestinal peptide for diagnosing exacerbation in chronic obstructive pulmonary disease

“…A biomarker with the potential to diagnose AE-COPD would therefore be beneficial for COPD management. Several serum markers have been reported to be upregulated at AE-COPD, such as C-reactive protein [4] , copeptin and procalcitonin [35] , tumor necrosis factor-α and leptin [36] , endothelin-1 [37] , fibrinogen [38,39] , IL-6 [40] , IL-8 [41] , eosinophil cationic protein, myeloperoxidase [42] and soluble urokinase-type plasminogen activator receptor [43] . However, there has been no report on the relationship of serum VIP and AE-COPD.…”